{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T19:47:13Z","timestamp":1769370433133,"version":"3.49.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12985-018-0946-2","type":"journal-article","created":{"date-parts":[[2018,3,2]],"date-time":"2018-03-02T04:28:04Z","timestamp":1519964884000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["IL28B gene polymorphism rs12979860, but not rs8099917, contributes to the occurrence of chronic HCV infection in Uruguayan patients"],"prefix":"10.1186","volume":"15","author":[{"given":"Natalia","family":"Echeverr\u00eda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Chiodi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Sanchez Ciceron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenniffer","family":"Angulo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelo","family":"L\u00f3pez-Lastra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Silvera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Canavesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Colistro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Cristina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nelia","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6155-7206","authenticated-orcid":false,"given":"Pilar","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,2]]},"reference":[{"key":"946_CR1","unstructured":"2017 GHR. Geneva: World Health Organization. Geneva; 2017. licence: CC BY-NC-SA 3.0 IGO."},{"key":"946_CR2","first-page":"117","volume":"40","author":"N Hernandez","year":"2010","unstructured":"Hernandez N, Mescia G, Pollio C, Robaina G, Quintana L, Bianchi C. Effectiveness of pegylated interferon alfa 2a and ribavirin for chronic hepatitis C in clinical practice. Acta Gastroenterol Latinoam. 2010;40:117\u201321.","journal-title":"Acta Gastroenterol Latinoam"},{"key":"946_CR3","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","volume":"358","author":"MP Manns","year":"2001","unstructured":"Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (London, England). 2001;358:958\u201365. https:\/\/doi.org\/10.1016\/S0140-6736(01)06102-5 .","journal-title":"Lancet (London, England)"},{"key":"946_CR4","doi-asserted-by":"publisher","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","volume":"140","author":"SJ Hadziyannis","year":"2004","unstructured":"Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346\u201355. https:\/\/doi.org\/10.7326\/0003-4819-140-5-200403020-00010 .","journal-title":"Ann Intern Med"},{"issue":"9","key":"946_CR5","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1136\/gut.2005.076646","volume":"55","author":"MP Manns","year":"2006","unstructured":"Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut. 2006;55(9):1350. https:\/\/doi.org\/10.1136\/gut.2005.076646 .","journal-title":"Gut"},{"key":"946_CR6","first-page":"34","volume-title":"Short guide to hepatitis C. Flying Publisher","author":"M Cornberg","year":"2012","unstructured":"Cornberg M, Hardtke S, Port K, Manns MP, Wedemeyer H, Standard HC. Of care. In: Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H, editors. Short guide to hepatitis C. Flying Publisher; 2012. p. 34\u201357."},{"key":"946_CR7","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nature08309","volume":"461","author":"D Ge","year":"2009","unstructured":"Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399\u2013401. https:\/\/doi.org\/10.1038\/nature08309 .","journal-title":"Nature"},{"key":"946_CR8","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1038\/ng.447","volume":"41","author":"V Suppiah","year":"2009","unstructured":"Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41:1100\u20134. https:\/\/doi.org\/10.1038\/ng.447 .","journal-title":"Nat Genet"},{"key":"946_CR9","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/ng.449","volume":"41","author":"Y Tanaka","year":"2009","unstructured":"Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105\u20139. https:\/\/doi.org\/10.1038\/ng.449 .","journal-title":"Nat Genet"},{"key":"946_CR10","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/nature08463","volume":"461","author":"DL Thomas","year":"2009","unstructured":"Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O\u2019Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461:798\u2013801. https:\/\/doi.org\/10.1038\/nature08463 .","journal-title":"Nature"},{"key":"946_CR11","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1002\/hep.24546","volume":"54","author":"TM Scherzer","year":"2011","unstructured":"Scherzer TM, St\u00e4ttermayer AF, Strasser M, Laferl H, Maieron A, Stauber R, et al. Impact of IL28B on treatment outcome in hepatitis C virus G1\/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)\/ribavirin. Hepatology. 2011;54:1518\u201326.","journal-title":"Hepatology"},{"key":"946_CR12","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1053\/j.gastro.2009.12.056","volume":"138","author":"A Rauch","year":"2010","unstructured":"Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010;138:1338\u201345, 1345-7. https:\/\/doi.org\/10.1053\/j.gastro.2009.12.056 .","journal-title":"Gastroenterology"},{"key":"946_CR13","doi-asserted-by":"publisher","unstructured":"Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained Virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010;139(1):120-9.e18. https:\/\/doi.org\/10.1053\/j.gastro.2010.04.013 .","DOI":"10.1053\/j.gastro.2010.04.013"},{"key":"946_CR14","doi-asserted-by":"crossref","unstructured":"Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology. 2010;139:827.e1\u2013827.","DOI":"10.1053\/j.gastro.2010.05.079"},{"key":"946_CR15","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1111\/jvh.12003","volume":"19","author":"JA Holmes","year":"2012","unstructured":"Holmes JA, Desmond PV, Thompson AJ. Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection? J Viral Hepat. 2012;19:677\u201384.","journal-title":"J Viral Hepat"},{"key":"946_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s40064-015-1137-x","volume":"4","author":"G Calisti","year":"2015","unstructured":"Calisti G, Tavares A, Macartney MJ, McCormick A, Labbett W, Jacobs M, et al. IL28B genotype predicts response to chronic hepatitis C triple therapy with telaprevir or boceprevir in treatment na\u00efve and treatment-experienced patients other than prior partial- and null-responders. Spring. 2015;4:357. https:\/\/doi.org\/10.1186\/s40064-015-1137-x .","journal-title":"Spring"},{"key":"946_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0145105","volume":"10","author":"F About","year":"2015","unstructured":"About F, Oudot-Mellakh T, Niay J, Rabi\u00e9ga P, Pedergnana V, Duffy D, et al. Impact of IL28B, APOH and ITPA polymorphisms on efficacy and safety of TVRor BOC-based triple therapy in treatment-experienced HCV-1 patients with compensated cirrhosis from the ANRS CO20-CUPIC study. PLoS One. 2015;10:1\u201313.","journal-title":"PLoS One"},{"key":"946_CR18","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1093\/cid\/cis915","volume":"56","author":"P Barreiro","year":"2013","unstructured":"Barreiro P, Vispo E, Poveda E, Fern\u00e1ndez-Montero JV, Soriano V. Hepatitis C therapy: highlights from the 2012 annual meeting of the European Association for the Study of the liver. Clin Infect Dis. 2013;56:560\u20136. https:\/\/doi.org\/10.1093\/cid\/cis915 .","journal-title":"Clin Infect Dis"},{"key":"946_CR19","first-page":"19","volume":"40","author":"G D\u2019Offizi","year":"2017","unstructured":"D\u2019Offizi G, Camm\u00e0 C, Taibi C, Schlag M, Palma M, Demasi R, et al. Clinical and virological predictors of sustained response with an interferon-based simeprevir regimen for patients with chronic genotype 1 hepatitis C virus infection. New Microbiol. 2017;40:19\u201326.","journal-title":"New Microbiol"},{"key":"946_CR20","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/jmv.24617","volume":"89","author":"N Akuta","year":"2017","unstructured":"Akuta N, Sezaki H, Suzuki F, Fujiyama S, Kawamura Y, Hosaka T, et al. Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan. J Med Virol. 2017;89:284\u201390.","journal-title":"J Med Virol"},{"key":"946_CR21","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1001\/jama.284.4.450","volume":"284","author":"DL Thomas","year":"2000","unstructured":"Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000;284:450\u20136.","journal-title":"JAMA"},{"key":"946_CR22","doi-asserted-by":"publisher","first-page":"e134","DOI":"10.1111\/j.1365-2893.2010.01402.x","volume":"18","author":"J Muir a","year":"2011","unstructured":"Muir a J, Hu K-Q, Gordon SC, Koury K, Boparai N, Noviello S, et al. Hepatitis C treatment among racial and ethnic groups in the IDEAL trial. J Viral Hepat. 2011;18:e134\u201343. https:\/\/doi.org\/10.1111\/j.1365-2893.2010.01402.x .","journal-title":"J Viral Hepat"},{"key":"946_CR23","first-page":"339","volume":"7","author":"J Trinks","year":"2014","unstructured":"Trinks J, Hulaniuk ML, Redal MA, Flichman D. Clinical utility of pharmacogenomics in the management of hepatitis C. Pharmgenomics Pers Med. 2014;7:339\u201347.","journal-title":"Pharmgenomics Pers Med"},{"issue":"Database Issue","key":"946_CR24","doi-asserted-by":"publisher","first-page":"D1010","DOI":"10.1093\/nar\/gkr924","volume":"40","author":"H Rajeevan","year":"2012","unstructured":"Rajeevan H, Soundararajan U, Kidd JR, Pakstis AJ, Kidd KK. ALFRED: an allele frequency resource for research and teaching. Nucleic Acids Res. 2012;40(Database Issue):D1010\u20135.","journal-title":"Nucleic Acids Res"},{"key":"946_CR25","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S1665-2681(19)31413-9","volume":"11","author":"LE Mart\u00ednez-G\u00f3mez","year":"2012","unstructured":"Mart\u00ednez-G\u00f3mez LE, Ch\u00e1vez-Tapia NC, Burguete-Garc\u00eda AI, Aguilar-Olivos N, Madrid-Marina V, Rom\u00e1n-Bahena M, et al. IL28B polymorphisms predict the response to chronic hepatitis C virus infection treatment in a Mexican population. Ann Hepatol. 2012;11:876\u201381.","journal-title":"Ann Hepatol"},{"key":"946_CR26","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/tpj.2014.20","volume":"14","author":"J Trinks","year":"2014","unstructured":"Trinks J, Hulaniuk ML, Caputo M, Pratx LB, R\u00e9 V, Fortuny L, et al. Distribution of genetic polymorphisms associated with hepatitis C virus (HCV) antiviral response in a multiethnic and admixed population. Pharmacogenomics J. 2014;14:549\u201354.","journal-title":"Pharmacogenomics J"},{"key":"946_CR27","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/jvh.12076","volume":"20","author":"J Angulo","year":"2013","unstructured":"Angulo J, Pino K, Pavez C, Biel F, Labb\u00e9 P, Miquel JF, et al. Genetic variations in host IL28B links to the detection of peripheral blood mononuclear cells-associated hepatitis C virus RNA in chronically infected patients. J Viral Hepat. 2013;20:263\u201372.","journal-title":"J Viral Hepat"},{"key":"946_CR28","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.3748\/wjg.v17.i31.3636","volume":"17","author":"M Venegas","year":"2011","unstructured":"Venegas M, Villanueva RA, Gonz\u00e1lez K, Brahm J. IL28B polymorphisms associated with therapy response in Chilean chronic hepatitis C patients. World J Gastroenterol. 2011;17:3636\u20139.","journal-title":"World J Gastroenterol"},{"key":"946_CR29","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S1665-2681(19)31512-1","volume":"10","author":"E Ridruejo","year":"2011","unstructured":"Ridruejo E, Solano \u00c1, Marciano S, Galdame O, Adrover R, Cocozzella D, et al. Genetic variation in interleukin-28B predicts SVR in hepatitis C genotype 1 argentine patients treated with PEG IFN and ribavirin. Ann Hepatol. 2011;10:452\u20137.","journal-title":"Ann Hepatol"},{"key":"946_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmicb.2015.00153","volume":"6","author":"BC Bertol","year":"2015","unstructured":"Bertol BC, Moreira S, Garcia RFL, Ferreira LE, Debortoli G, de Leite Pinho MS, et al. IL28B gene polymorphisms in mono- and HIV-coinfected chronic hepatitis C patients. Front Microbiol. 2015;6:1\u20138.","journal-title":"Front Microbiol"},{"key":"946_CR31","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1478-3231.2011.02653.x","volume":"32","author":"LN Cavalcante","year":"2012","unstructured":"Cavalcante LN, Abe-Sandes K, Angelo ALD, Machado TMB, Lemaire DC, Mendes CMC, et al. IL28B polymorphisms are markers of therapy response and are influenced by genetic ancestry in chronic hepatitis C patients from an admixed population. Liver Int. 2012;32:476\u201386.","journal-title":"Liver Int"},{"issue":"1 SUPPL. 1","key":"946_CR32","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1590\/S1415-47572014000200003","volume":"37","author":"FM Salzano","year":"2014","unstructured":"Salzano FM, Sans M. Interethnic admixture and the evolution of Latin American populations. Genet Mol Biol. 2014;37(1 SUPPL. 1):151\u201370.","journal-title":"Genet Mol Biol"},{"key":"946_CR33","first-page":"190","volume":"12","author":"H Sharafi","year":"2012","unstructured":"Sharafi H, Pouryasin A, Alavian SM, Behnava B, Keshvari M, Mehrnoush L, et al. Development and validation of a simple, rapid and inexpensive PCRRFLP method for genotyping of common IL28b polymorphisms: a useful pharmacogenetic tool for prediction of hepatitis C treatment response. Hepat Mon. 2012;12:190\u20135.","journal-title":"Hepat Mon"},{"key":"946_CR34","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1086\/519795","volume":"81","author":"S Purcell","year":"2007","unstructured":"Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81:559\u201375. https:\/\/doi.org\/10.1086\/519795 .","journal-title":"Am J Hum Genet"},{"key":"946_CR35","unstructured":"R Core Team. R: A Language and Environment for statistical computing. R Foundation for Statistical Computing, Vienna. 2014. http:\/\/www.r-project.org\/ ."},{"key":"946_CR36","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/bioinformatics\/bth457","volume":"21","author":"JC Barrett","year":"2005","unstructured":"Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263\u20135.","journal-title":"Bioinformatics"},{"key":"946_CR37","first-page":"1","volume":"7","author":"X Shi","year":"2012","unstructured":"Shi X, Pan Y, Wang M, Wang D, Li W, Jiang T, et al. IL28B genetic variation is associated with spontaneous clearance of hepatitis C virus, treatment response, serum IL-28B levels in Chinese population. PLoS One. 2012;7:1\u20138.","journal-title":"PLoS One"},{"key":"946_CR38","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1590\/S0074-02762012000700008","volume":"107","author":"JA Ramos","year":"2012","unstructured":"Ramos JA, Ramos AL, Hoffmann L, Perez Rde M, HSM C, \u00dcrm\u00e9nyi TP, et al. A single nucleotide polymorphism, rs129679860, in the IL28B locus is associated with the viral kinetics and a sustained virological response in a chronic, monoinfected hepatitis C virus genotype-1 Brazilian population treated with pegylated interferon-rib. Mem Inst Oswaldo Cruz. 2012;107:888\u201392.","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"946_CR39","doi-asserted-by":"publisher","first-page":"F23","DOI":"10.1097\/QAD.0b013e3283391d6d","volume":"24","author":"NI Rall\u00f3n","year":"2010","unstructured":"Rall\u00f3n NI, Naggie S, Benito JM, Medrano J, Restrepo C, Goldstein D, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV\/hepatitis C virus-coinfected patients. AIDS. 2010;24:F23\u20139.","journal-title":"AIDS"},{"key":"946_CR40","doi-asserted-by":"publisher","unstructured":"Castells M, Bello G, Ifr\u00e1n S, Pereyra S, Boschi S, Uriarte R, et al. Epidemic history of major genotypes of hepatitis C virus in Uruguay. Infect Genet Evol. 2015;32:231\u2013238. doi: https:\/\/doi.org\/10.1016\/j.meegid.2015.03.021 .","DOI":"10.1016\/j.meegid.2015.03.021"},{"key":"946_CR41","doi-asserted-by":"publisher","first-page":"147","DOI":"10.5152\/balkanmedj.2015.15156","volume":"32","author":"S Taheri","year":"2015","unstructured":"Taheri S, Aygen B, Korkmaz K, Y\u0131ld\u0131z O, Zarars\u0131z G, Canatan H. Characterization of the interleukin-28B gene rs12979860 C\/T polymorphism in Turkish chronic hepatitis C patients and healthy individuals. Balkan Med J. 2015;32:147\u201355.","journal-title":"Balkan Med J"},{"key":"946_CR42","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/hep.23624","volume":"52","author":"MA Montes-Cano","year":"2010","unstructured":"Montes-Cano MA, Garc\u00eda-Lozano JR, Abad-Molina C, Romero-G\u00f3mez M, Barroso N, Aguilar-Reina J, et al. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology. 2010;52:33\u20137.","journal-title":"Hepatology"},{"key":"946_CR43","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s12072-015-9619-z","volume":"9","author":"S Knapp","year":"2015","unstructured":"Knapp S, Zakaria Z, Hashem M, Zaghla H, Khakoo SI, Waked I, et al. Influence of IFNL3.rs12979860 and IFNL4.ss469415590 polymorphism on clearance of hepatitis C virus infection among Egyptians. Hepatol Int. 2015;9:251\u20137.","journal-title":"Hepatol Int"},{"key":"946_CR44","doi-asserted-by":"publisher","DOI":"10.5812\/hepatmon.22649","volume":"14","author":"H Sharafi","year":"2014","unstructured":"Sharafi H, Moayed Alavian S, Behnava B, Pouryasin A, Keshvari M. The impact of IFNL4 rs12979860 polymorphism on spontaneous clearance of hepatitis C; a case-control study. Hepat Mon. 2014;14:e22649.","journal-title":"Hepat Mon"},{"key":"946_CR45","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.jfma.2016.07.013","volume":"115","author":"Y-H Mah","year":"2016","unstructured":"Mah Y-H, Liu C-H, Chen C-L, Tseng T-C, Liu C-J, Chen P-J, et al. Prevalence and clinical implications of IL28B genotypes in Taiwanese patients with chronic hepatitis C. J Formos Med Assoc. 2016;115:953\u201360. https:\/\/doi.org\/10.1016\/j.jfma.2016.07.013 .","journal-title":"J Formos Med Assoc"},{"key":"946_CR46","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1007\/s00705-016-2809-8","volume":"161","author":"AC de Seixas Santos Nastri","year":"2016","unstructured":"de Seixas Santos Nastri AC, de Mello Malta F, Diniz MA, Yoshino A, Abe-Sandes K, Dos Santos SE, et al. Association of IFNL3 and IFNL4 polymorphisms with hepatitis C virus infection in a population from southeastern Brazil. Arch Virol. 2016;161:1477\u201384.","journal-title":"Arch Virol"},{"key":"946_CR47","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3350\/cmh.2014.20.2.177","volume":"20","author":"NY Heo","year":"2014","unstructured":"Heo NY, Lim YS, Lee W, Oh M, An J, Lee D, et al. No association between the IL28B SNP and response to peginterferon plus ribavirin combination treatment in Korean chronic hepatitis C patients. Clin Mol Hepatol. 2014;20:177\u201384. https:\/\/doi.org\/10.3350\/cmh.2014.20.2.177 .","journal-title":"Clin Mol Hepatol"},{"key":"946_CR48","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1002\/hep.24154","volume":"53","author":"A Moghaddam","year":"2011","unstructured":"Moghaddam A, Melum E, Reinton N, Ring-Larsen H, Verbaan H, Bj\u00f8ro K, et al. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology. 2011;53:746\u201354. https:\/\/doi.org\/10.1002\/hep.24154 .","journal-title":"Hepatology"},{"key":"946_CR49","volume":"12","author":"H Sharafi","year":"2012","unstructured":"Sharafi H, Pouryasin A, Alavian SM, Behnava B, Keshvari M, Salimi S, et al. Distribution of IL28B genotypes in Iranian patients with chronic hepatitis C and healthy individuals. Hepat Mon. 2012;12:e8387.","journal-title":"Hepat Mon"},{"key":"946_CR50","doi-asserted-by":"publisher","first-page":"90","DOI":"10.4103\/2277-9175.183138","volume":"5","author":"M Minakari","year":"2016","unstructured":"Minakari M, Golshani M, Yaran M, Ataei B. Prevalence of interleukin-28B single nucleotide polymorphism genotypes in patients with hepatitis C infection in Isfahan, Iran. Adv Biomed Res. 2016;5:90.","journal-title":"Adv Biomed Res"},{"key":"946_CR51","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/1751-2980.12202","volume":"16","author":"ZX Dong","year":"2015","unstructured":"Dong ZX, Zhou HJ, Xiang XG, Guo SM, Zhuang Y, De ZG, et al. IL28B genetic variations are associated with treatment response of patients with chronic hepatitis C in a Chinese Han population. J Dig Dis. 2015;16:90\u20137. https:\/\/doi.org\/10.1111\/1751-2980.12202 .","journal-title":"J Dig Dis"},{"key":"946_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s40064-016-3663-6","volume":"5","author":"A Mangia","year":"2016","unstructured":"Mangia A, De Ledinghen V, Bailly F, Brahm J, Keiss J, Valantinas J, et al. IL28B genotype is associated with cirrhosis or transition to cirrhosis in treatment-naive patients with chronic HCV genotype 1 infection: the international observational gen-C study. Spring. 2016;5:1990. https:\/\/doi.org\/10.1186\/s40064-016-3663-6 .","journal-title":"Spring"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-018-0946-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T18:07:36Z","timestamp":1719857256000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-018-0946-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,2]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["946"],"URL":"https:\/\/doi.org\/10.1186\/s12985-018-0946-2","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,2]]},"assertion":[{"value":"12 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted according to national and international ethical guidelines (good clinical practice, Nuremberg statements, Declaration of Helsinki) and local regulatory rules (Mercosur Standards\/GMC\/RES No. 129\/96). The protocol was approved by the Ethics Committee of the Hospital de Cl\u00ednicas on October 24th (2014) and all patients gave written informed consent. Access to personal information was restricted to the medical doctors. The genetic information extracted from the samples was used exclusively for the purposes of this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"40"}}